NLK and diabetes mellitus: Despite there being no specific small-molecule inhibitor of NLK activity, the commonly prescribed diabetes drug, metformin, has demonstrated efficacy in downregulating NLK expression (9, 13) and improving erythropoiesis in human, mouse, and animal models of DBA (13).